The board of directors of Hua Medicine (Shanghai) Ltd. announced that Ms. Wei Zhao has tendered her resignation from the office of a non-executive Director and a member of the remuneration committee of the Board with effect from October 12, 2023. Ms. Zhao resigned from her positions in order to devote more time to her other work commitments and has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited. The Board hereby announces that Dr. Fangxin LI ("Dr. Li") has been appointed as a non-executive Director with effect from October 12, 2023. Dr. Li, aged 31, has been appointed as a non-executive Director with such appointment to take effect from October 12, 2023. He is primarily responsible for providing overall guidance on the business and strategic development of the Group. He will also serve as a member of the Remuneration Committee with effect from October 12, 2023. Dr. Li has been serving as the senior investment manager of WuXi AppTec Singapore Pte. Ltd. He was a consultant of Bain & Company and was primarily responsible for providing strategy and conducting commercial due diligence for healthcare players, from April 2019 to December 2020. He was a cofounder and the chief executive officer of HAIKUI Regenerative Medicine, and was primarily responsible for research and development in cartilage and dermal implantation technologies, from August 2016 to January 2019. Dr. Li received his bachelor's degree in Engineering from Imperial College London in the United Kingdom in June 2014. He obtained a PhD degree in Tissue Engineering from University of Oxford in the United Kingdom in September 2018. The Board hereby announces that following the appointment of Dr. Li as a non-executive Director,
he has also been appointed as a member of the Remuneration Committee with effect from October 12, 2023.